COVID-19 International Drug Pregnancy Registry
Recruiting
Observational Study
Covid19
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 50
- Sex
- Female
- Study type
- Observational
- Participants needed
- 2,000 (estimated)
- Sponsor
- Pregistry · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Pregnant or recently pregnant (up to 30 days after the end of pregnancy) at time of enrollment
* Age ≥18 years at time of enrollment
* With mild to severe COVID-19 during pregnancy
* Either
* Treated for COVID-19 with at least one of the medications included in Table 1 duri…
Contacts